Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: A meta-analysis of randomised controlled trials

Drug Safety

Volumn 24, Issue 11, 2001, Pages 863-868

  Etminan, M ^a,b   Samii, A ^c   Takkouche, B ^d   Rochon, P A ^a,e,f  

^a Kunin Lunenfeld Applied Research Unit and Department of Food and Nutrition Services and Baycrest Centre for Geriatric Care   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^e UNIVERSITY OF TORONTO   (Canada)

^f INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO; PRAMIPEXOLE; ROPINIROLE;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG SURVEILLANCE PROGRAM; HUMAN; META ANALYSIS; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; SOMNOLENCE;

EID: 0034784414     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124110-00007     Document Type: Article

References (28)

1. Ropinirole for the treatment of early Parkinson's disease
2. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease
3. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease
4. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole
5. Sleep attacks in Parkinson's disease
6. Sleep attacks (sleep episodes) with pergolide
7. Pramipexole vs levodopa as initial treatment for Parkinson's disease: A randomized controlled trial
8. Evaluation of old and new tests of heterogeneity in epidemiologic metaanalysis
9. 2 agonist in the treatment of motor fluctuations of L-dopa treated Parkinsonian patients
10. Ropinirole in the treatment of early Parkinson's disease: A six month interim report of a five year levodopa-controlled study
11. Ropinirole for the treatment of early Parkinson's disease
12. Safety and efficacy of pramipexole in early Parkinson's disease: A randomized dose-ranging study
13. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
14. 2 agonist, as sole dopaminergic therapy in Parkinson's disease patients
15. Ropinirole in the symptomatic treatment of Parkinson's disease
16. Efficacy, safety and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: A double blind, placebo, controlled, randomized, multicentre study
17. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease
18. A five year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
19. Pramipexole-induced somnolence and episodes of daytime sleep
20. Sleep episodes in Parkinson's disease: A wake up call
21. Comparison of pramipexole, fluoxetine and placebo in patients with major depression
22. Sleep attacks and Parkinson's disease treatment
23. A multicenter double-blind placebo controlled trial of pergolide as an adjunct to sinemet in Parkinson's disease
24. Pergolide monotherapy in the treatment of early Parkinson's disease: A randomized controlled study